Free Trial
NASDAQ:UBX

UNITY Biotechnology Q3 2024 Earnings Report

UNITY Biotechnology logo
$0.30 0.00 (-1.01%)
Closing price 03:54 PM Eastern
Extended Trading
$0.30 0.00 (0.00%)
As of 04:44 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

UNITY Biotechnology EPS Results

Actual EPS
-$0.38
Consensus EPS
-$0.40
Beat/Miss
Beat by +$0.02
One Year Ago EPS
N/A

UNITY Biotechnology Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

UNITY Biotechnology Announcement Details

Quarter
Q3 2024
Time
After Market Closes
Conference Call Date
Monday, November 4, 2024
Conference Call Time
12:00AM ET

Upcoming Earnings

UNITY Biotechnology's Q2 2025 earnings is scheduled for Tuesday, July 22, 2025, with a conference call scheduled at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

UNITY Biotechnology Earnings Headlines

Unity Stock Crashes Nearly 50% After Nasdaq Delisting Notice
A grave, grave error.
I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.
UBX Unity Biotechnology, Inc. - Seeking Alpha
See More UNITY Biotechnology Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like UNITY Biotechnology? Sign up for Earnings360's daily newsletter to receive timely earnings updates on UNITY Biotechnology and other key companies, straight to your email.

About UNITY Biotechnology

UNITY Biotechnology (NASDAQ:UBX), a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate includes UBX1325, which is Phase 2 clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy. It also develops UBX1967 for the treatment of ophthalmologic diseases; UBX2048, a Tie2/VEGF bispecific; UBX2050, a human anti-Tie2 agonist monoclonal antibody for the treatment of eye diseases; and UBX2089, a a-Klotho hormone drug candidate for multiple neurology indications. The company was formerly known as Forge, Inc. and changed its name to Unity Biotechnology, Inc. in January 2015. Unity Biotechnology, Inc. was incorporated in 2009 and is headquartered in South San Francisco, California.

View UNITY Biotechnology Profile

More Earnings Resources from MarketBeat